Literature DB >> 27211870

Complement in disease: a defence system turning offensive.

Daniel Ricklin1, Edimara S Reis1, John D Lambris1.   

Abstract

Although the complement system is primarily perceived as a host defence system, a more versatile, yet potentially more harmful side of this innate immune pathway as an inflammatory mediator also exists. The activities that define the ability of the complement system to control microbial threats and eliminate cellular debris - such as sensing molecular danger patterns, generating immediate effectors, and extensively coordinating with other defence pathways - can quickly turn complement from a defence system to an aggressor that drives immune and inflammatory diseases. These host-offensive actions become more pronounced with age and are exacerbated by a variety of genetic factors and autoimmune responses. Complement can also be activated inappropriately, for example in response to biomaterials or transplants. A wealth of research over the past two decades has led to an increasingly finely tuned understanding of complement activation, identified tipping points between physiological and pathological behaviour, and revealed avenues for therapeutic intervention. This Review summarizes our current view of the key activating, regulatory, and effector mechanisms of the complement system, highlighting important crosstalk connections, and, with an emphasis on kidney disease and transplantation, discusses the involvement of complement in clinical conditions and promising therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27211870      PMCID: PMC4974115          DOI: 10.1038/nrneph.2016.70

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  170 in total

Review 1.  The emerging role of complement inhibitors in transplantation.

Authors:  Véronique Frémeaux-Bacchi; Christophe M Legendre
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

Review 2.  Role of complement and complement regulators in the removal of apoptotic cells.

Authors:  L A Trouw; A M Blom; P Gasque
Journal:  Mol Immunol       Date:  2007-10-24       Impact factor: 4.407

Review 3.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

Review 4.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 5.  Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a.

Authors:  Hydar Ali
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

6.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

7.  Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

Authors:  Marie Frimat; Fanny Tabarin; Jordan D Dimitrov; Caroline Poitou; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Blood       Date:  2013-05-21       Impact factor: 22.113

Review 8.  Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.

Authors:  Magdalena Riedl; Fadi Fakhouri; Moglie Le Quintrec; Damien G Noone; Therese C Jungraithmayr; Veronique Fremeaux-Bacchi; Christoph Licht
Journal:  Semin Thromb Hemost       Date:  2014-06-09       Impact factor: 4.180

Review 9.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

Review 10.  The paradoxical roles of C1q and C3 in autoimmunity.

Authors:  Diane Scott; Marina Botto
Journal:  Immunobiology       Date:  2015-05-11       Impact factor: 3.144

View more
  183 in total

1.  Complement up-regulates Runx-2 to induce pro-fibrogenic change in aortic valve interstitial cells.

Authors:  Xin-Sheng Deng; Xianzhong Meng; David Fullerton; Matthew Stone; James Jaggers
Journal:  Ann Thorac Surg       Date:  2021-02-02       Impact factor: 4.330

2.  Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.

Authors:  Richard B Pouw; Mieke C Brouwer; Marlon de Gast; Anna E van Beek; Lambertus P van den Heuvel; Christoph Q Schmidt; Arie van der Ende; Pilar Sánchez-Corral; Taco W Kuijpers; Diana Wouters
Journal:  Blood Adv       Date:  2019-02-26

3.  Safety profile after prolonged C3 inhibition.

Authors:  Edimara S Reis; Nadja Berger; Xin Wang; Sophia Koutsogiannaki; Robert K Doot; Justin T Gumas; Periklis G Foukas; Ranillo R G Resuello; Joel V Tuplano; David Kukis; Alice F Tarantal; Anthony J Young; Tetsuhiro Kajikawa; Athena M Soulika; Dimitrios C Mastellos; Despina Yancopoulou; Ali-Reza Biglarnia; Markus Huber-Lang; George Hajishengallis; Bo Nilsson; John D Lambris
Journal:  Clin Immunol       Date:  2018-10-10       Impact factor: 3.969

4.  Murine T Cell Maturation Entails Protection from MBL2, but Complement Proteins Do Not Drive Clearance of Cells That Fail Maturation in the Absence of NKAP.

Authors:  Barsha Dash; Paul J Belmonte; Sydney R Fine; Michael J Shapiro; Ji Young Chung; Aaron D Schwab; Shaylene A McCue; Matthew J Rajcula; Virginia Smith Shapiro
Journal:  J Immunol       Date:  2019-06-07       Impact factor: 5.422

Review 5.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

6.  Crystallization and X-ray analysis of monodisperse human properdin.

Authors:  Dennis Vestergaard Pedersen; Margot Revel; Trine Amalie Fogh Gadeberg; Gregers Rom Andersen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2019-01-23       Impact factor: 1.056

7.  Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B.

Authors:  Xin Xu; Chi Zhang; Dalton T Denton; Daniel O'Connell; Daniel W Drolet; Brian V Geisbrecht
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.422

Review 8.  Complement in ANCA-associated vasculitis: mechanisms and implications for management.

Authors:  Min Chen; David R W Jayne; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-03-20       Impact factor: 28.314

Review 9.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

10.  Native State of Complement Protein C3d Analysed via Hydrogen Exchange and Conformational Sampling.

Authors:  Didier Devaurs; Malvina Papanastasiou; Dinler A Antunes; Jayvee R Abella; Mark Moll; Daniel Ricklin; John D Lambris; Lydia E Kavraki
Journal:  Int J Comput Biol Drug Des       Date:  2018-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.